Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

Bibliographic Details
Main Authors:	Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Bo Zhang, Lindsay N. Carpp, Craig A. Magaret, Michal Juraska, Peter B. Gilbert, David C. Montefiori, Katharine J. Bar, E. Fabian Cardozo-Ojeda, Joshua T. Schiffer, Raabya Rossenkhan, Paul Edlefsen, Lynn Morris, Nonhlanhla N. Mkhize, Carolyn Williamson, James I. Mullins, Kelly E. Seaton, Georgia D. Tomaras, Philip Andrew, Nyaradzo Mgodi, Julie E. Ledgerwood, Myron S. Cohen, Lawrence Corey, Logashvari Naidoo, Catherine Orrell, Paul A. Goepfert, Martin Casapia, Magdalena E. Sobieszczyk, Shelly T. Karuna, Srilatha Edupuganti
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-03-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-024-46805-8

Similar Items

High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
by: Daniel B. Reeves, et al.
Published: (2023-12-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
by: Yunda Huang, et al.
Published: (2022-10-01)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment
by: Raabya Rossenkhan, et al.
Published: (2019-07-01)

Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection.
by: Raabya Rossenkhan, et al.
Published: (2012-01-01)

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
by: Deborah Donnell, et al.
Published: (2023-06-01)

Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
by: Brian D. Williamson, et al.
Published: (2023-09-01)

Prospects for passive immunity to prevent HIV infection.
by: Lynn Morris, et al.
Published: (2017-11-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe
by: Caroline Murombedzi, et al.
Published: (2023-11-01)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
by: Kenneth H Mayer, et al.
Published: (2017-11-01)

Transposon identification using profile HMMs
by: Liu Jun S, et al.
Published: (2010-02-01)

HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy
by: Peter B Gilbert, et al.
Published: (2019-05-01)

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
by: Beryl A Koblin, et al.
Published: (2011-01-01)

Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations
by: Nyaradzo M. Mgodi, et al.
Published: (2023-07-01)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
by: Susan P Buchbinder, et al.
Published: (2017-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
by: Goepfert P, et al.
Published: (2012-09-01)

Understanding the CD8 T-cell response in natural HIV control [version 1; referees: 3 approved]
by: Sushma Boppana, et al.
Published: (2018-07-01)

Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review.
by: Jennifer E Balkus, et al.
Published: (2021-01-01)

Early and late complications after open and endoscopic neurosurgery for complex skull base and craniofacial pathology: Case series, illustrative cases, and review
by: Paul T. Akins, et al.
Published: (2022-09-01)

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.
by: Julie E Ledgerwood, et al.
Published: (2015-01-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
by: Nicole Espy, et al.
Published: (2023-01-01)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
by: Nicole Espy, et al.
Published: (2023-01-01)

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.
by: Michael Vaine, et al.
Published: (2010-11-01)

Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.
by: Joshua T Schiffer, et al.
Published: (2016-01-01)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
by: Zanele Ditse, et al.
Published: (2020-02-01)

Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials
by: William Chad Young, et al.
Published: (2021-06-01)

Statecraft : strategies for a changing world /
by: Thatcher, Magaret
Published: (2002)

Facilitative recovery of cyclodextrin glucanotransferase using chromatographic strategies
by: Sivapragasam, Magaret
Published: (2014)

Intermodal Competition of Mining Freight Transportation: The Case of Peru
by: Casapia Gaston
Published: (2022-12-01)

Book Review - Behavioral Coaching: How to build sustainable personal and organisational strength
by: Grant Ledgerwood
Published: (2004-02-01)

‘We lost a type of job for a type of person in this country’: changing expectations of working in the UK scientific civil service
by: Emmeline Ledgerwood
Published: (2023-06-01)

Unsettled: Cambodian Refugees in the New York City Hyperghetto, by Eric Tang
by: Judy Ledgerwood
Published: (2016-09-01)

From Strategic Planning to Strategic Coaching: Evolving conceptual frameworks to enable changing business cultures
by: Grant Ledgerwood
Published: (2003-08-01)

Clearance of blood stream infections in patients receiving extracorporeal membrane oxygenation: a retrospective single-center cohort study
by: Stone A. Frankford, et al.
Published: (2023-02-01)